Advertisement

Topics

Acasti Pharma Announces Data on TRILOGY Phase 3 Trials of CaPre in Patients

11:53 EST 31 Dec 2018 | Investing News Network

Acasti Pharma (NASDAQ:ACST;TSXV:ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia (HTG), today announced that the two Phase 3 TRILOGY trials have now exceeded 65% patient randomization, and more than 100 patients have completed their 6 month treatment plan. … Continued

The post Acasti Pharma Announces Data on TRILOGY Phase 3 Trials of CaPre in Patients appeared first on Investing News Network.

Original Article: Acasti Pharma Announces Data on TRILOGY Phase 3 Trials of CaPre in Patients

NEXT ARTICLE

More From BioPortfolio on "Acasti Pharma Announces Data on TRILOGY Phase 3 Trials of CaPre in Patients"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Prescription Drugs
A prescription drug (also prescription medication or prescription medicine) is a licensed medicine that is regulated by legislation to require a medical prescription before it can be obtained. The term is used to distinguish it from over-the-counter drug...

Hyperlipidemia - high cholesterol (hypercholesterolaemia)
Hyperlipidemia involves abnormally elevated levels of any or all lipids and/or lipoproteins in the blood. Lipids are transported in a protein capsule, the size of that capsule, or lipoprotein, determines its density. The lipoprotein density and type...